Modest improvement in survival of patients with refractory anemia with excess blasts in the hypomethylating agents era in the United States

Amer M. ZeidanSection of Hematology, Department of Internal Medicine, Yale School of Medicine, New Haven, CT, USA; ;Cancer Outcomes, Public Policy, and Effectiveness Research (COPPER) Center, Yale University, New Haven, CT, USA; Correspondence[email protected]

Rong WangCancer Outcomes, Public Policy, and Effectiveness Research (COPPER) Center, Yale University, New Haven, CT, USA; ;Department of Chronic Disease Epidemiology, Yale School of Public Health, New Haven, CT, USA;

Cary P. GrossCancer Outcomes, Public Policy, and Effectiveness Research (COPPER) Center, Yale University, New Haven, CT, USA;

Steven D. GoreSection of Hematology, Department of Internal Medicine, Yale School of Medicine, New Haven, CT, USA; ;Cancer Outcomes, Public Policy, and Effectiveness Research (COPPER) Center, Yale University, New Haven, CT, USA;

Scott F. HuntingtonSection of Hematology, Department of Internal Medicine, Yale School of Medicine, New Haven, CT, USA; ;Cancer Outcomes, Public Policy, and Effectiveness Research (COPPER) Center, Yale University, New Haven, CT, USA;

Thomas PrebetSection of Hematology, Department of Internal Medicine, Yale School of Medicine, New Haven, CT, USA;

Gregory A. AbelDivision of Population Sciences, Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA;

Amy J. DavidoffCancer Outcomes, Public Policy, and Effectiveness Research (COPPER) Center, Yale University, New Haven, CT, USA; ;Department of Health Policy and Management, Yale School of Public Health, New Haven, CT, USA

Xiaomei MaCancer Outcomes, Public Policy, and Effectiveness Research (COPPER) Center, Yale University, New Haven, CT, USA; ;Department of Chronic Disease Epidemiology, Yale School of Public Health, New Haven, CT, USA;

show all

Click to increase image sizeClick to decrease image size

Acknowledgements

The authors acknowledge the efforts of the Applied Research Program, National Cancer Institute; the Office of Research, Development and Information, Information Management Services, Inc.; and the SEER Program tumor registries in the creation of the SEER database.

Potential conflict of interest

Disclosure forms provided by the authors are available with the full text of this article at http://dx.doi.org/10.1080/10428194.2016.1214954.

AMZ, SDG, TP, XM, and SH have consulted for Celgene the manufacturer for azacitidine.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Modest improvement in survival of patients with refractory anemia with excess blasts in the hypomethylating agents era in the United States

Information for

Open access

Opportunities

Help and information

Modest improvement in survival of patients with refractory anemia with excess blasts in the hypomethylating agents era in the United States

Acknowledgements

Potential conflict of interest

Reprints and Corporate Permissions

Academic Permissions

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date

Your download is now in progress and you may close this window

Login or register to access this feature